Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024
26. Juni 2024 09:00 ET
|
Elevai Labs Inc.
Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024
Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs
14. Juni 2024 09:00 ET
|
Elevai Labs Inc.
Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs
Elevai Labs Subsidiary, Elevai Skincare, to Present at the Beauty Through Science Conference in Stockholm
29. Mai 2024 09:00 ET
|
Elevai Labs Inc.
Elevai Labs Subsidiary, Elevai Skincare, to Present at the Beauty Through Science Conference in Stockholm
Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference
22. Mai 2024 16:15 ET
|
Elevai Labs Inc.
Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference
Elevai Labs Inc. Reports First Quarter 2024 Financial Results
15. Mai 2024 16:30 ET
|
Elevai Labs Inc.
Elevai Labs Inc. Reports First Quarter 2024 Financial Results
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
02. Mai 2024 08:30 ET
|
Elevai Labs Inc.
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare
01. Mai 2024 16:00 ET
|
Elevai Labs Inc.
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
01. Mai 2024 09:00 ET
|
Elevai Labs Inc.
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments
29. April 2024 09:45 ET
|
Elevai Labs Inc.
Elevai Labs Releases Global Distribution Partnership Overview: Contracts Secure $11.5M Top Line Revenue Boost
ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months
22. April 2024 08:00 ET
|
Elevai Labs Inc.
ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months